With regard to the papers by Kumar et al. and de Leeuw and de Boer addressing the cardiovascular safety and efficacy of anti-diabetic drugs

Eur Heart J Cardiovasc Pharmacother. 2017 Apr 1;3(2):75-76. doi: 10.1093/ehjcvp/pvw047.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cardiovascular Diseases
  • Cardiovascular System*
  • Diabetes Mellitus, Type 2*
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Treatment Outcome

Substances

  • Hypoglycemic Agents